A lot of pharmaceutical and biotech companies require a large IT infrastructure to handle the amount of data a biotech produces, which at times, can be daunting. Experimental data, patents, complex biochemical applications all require computer usage, which can be costly for a company (buying servers, hiring IT staff, upkeep, etc.). However, some larger companies like Eli Lilly and Pfizer are looking to cut those costs with cloud computing. Cloud computing basically offsets any worlkload that a computer might do locally to a server offsite. This way, a company doesnt have to worry about IT maintanace and can focus on research. Cloud computing is actually pretty affordable and scalable too. Now that larger biotechs have adopted cloud computing, can this market penetrate into low and mid-level biotechs?
Monday, July 13, 2009
Cloud Computing and Biotech
A lot of pharmaceutical and biotech companies require a large IT infrastructure to handle the amount of data a biotech produces, which at times, can be daunting. Experimental data, patents, complex biochemical applications all require computer usage, which can be costly for a company (buying servers, hiring IT staff, upkeep, etc.). However, some larger companies like Eli Lilly and Pfizer are looking to cut those costs with cloud computing. Cloud computing basically offsets any worlkload that a computer might do locally to a server offsite. This way, a company doesnt have to worry about IT maintanace and can focus on research. Cloud computing is actually pretty affordable and scalable too. Now that larger biotechs have adopted cloud computing, can this market penetrate into low and mid-level biotechs?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment